Today’s AI Top Pick: TEM

Tempus AI (TEM) is the cleaner buy today across both signal and fundamentals. The multi-timeframe forecast tape shows constructive alignment: 1d fc_short +17.73%, fc_mid +28.68%, fc_long +15.84%, and the 1wk confirms with fc_mid +25.12% and fc_long +18.5%. The near-term 1h/4h show mild negative short forecasts (-6.24% / -2.84%), which is actually helpful — it means we're not chasing a blowoff; the setup is a coiled dip within a bullish daily/weekly structure. Bullish_prob is 1.0 and near_term_bullish is 1.0 (vs. SMMT's 0.6). Positioning is favorable: TEM sits at just 3.13% of the 4h 21-bar range and 22.3% on 1h, with a 4h drawdown of -13.53% from the recent high — classic 'buy the pullback in an uptrend' geometry rather than chasing. RSI 45.54 is neutral and leaves room to run. Short float of 31.67% provides squeeze fuel if the daily forecast plays out. Fundamentally, TEM has real revenue traction — salesYoY +69.82%, gross margin 62.22%, EPS next year +83.89%, analyst recom 2.05 with targetUpsidePct +27.8%. Yes, profit margin is -22.2% and debt/equity 3.17 are cautions, but the growth trajectory and analyst support (Guggenheim just raised PT to $65 on 7/16) are catalysts, not headwinds. The recent whale-activity flag and PT hike are net-positive news. SMMT, by contrast, has a broken weekly forecast (fc_mid -3.61%, fc_long -14.3%) and a 45.13% drawdown from the weekly high — the daily bounce forecast (+35% mid) is contradicted by the longer timeframe. That's exactly the 'single-bar outlier vs. deteriorating trend' warning. Also, roe -270.95% and no revenue (salesYoY null) make it a pure clinical binary. The Ridinilazole divestiture is a minor housekeeping event, not a catalyst. TEM wins on multi-TF agreement, fundamentals, and news flow.